Q1 2025 Kura Oncology Inc Earnings Call Transcript
Key Points
- Kura Oncology Inc (KURA) has submitted a New Drug Application (NDA) for ziftomenib, a menin inhibitor, for the treatment of relapsed or refractory NPM1-mutant acute myeloid leukemia (AML), marking a significant regulatory milestone.
- The company has achieved a $45 million milestone payment from its collaboration with Kyowa Kirin, enhancing its financial position.
- Kura Oncology Inc (KURA) has a strong cash position with $703.2 million in cash, cash equivalents, and short-term investments, providing sufficient capital to fund its ziftomenib AML program through commercialization.
- The company is advancing its FTI program, with plans to share preliminary clinical data from multiple Phase 1 cohorts later this year, indicating potential for FTIs as combination therapies.
- Kura Oncology Inc (KURA) has announced the appointment of Samir Vattompadam as Senior Vice President, Global Program Leadership, bringing over 20 years of experience in the biotech and pharmaceutical industry to the team.
- Research and development expenses increased to $56 million in Q1 2025 from $36.3 million in Q1 2024, indicating rising costs.
- The company reported a net loss of $57.4 million for Q1 2025, compared to a net loss of $49.5 million in Q1 2024, reflecting ongoing financial challenges.
- General and administrative expenses rose to $22.8 million in Q1 2025 from $18.2 million in the same period in 2024, suggesting increased operational costs.
- Despite progress, the competitive landscape for menin inhibitors in the relapsed/refractory AML setting remains challenging, with other companies also advancing in this space.
- The company faces potential uncertainties in the regulatory approval process, although it has not experienced any disruptions or delays so far.
Good day everyone and welcome to todayâs first-quarter 2025 Kura Oncology financial results conference call. (Operator Instructions) Please note this call may be recorded and I will be standing by if you should need any assistance.
It is now my pleasure to turn the conference over to [Apoorva Shilori]. Please go ahead.
Thank you, operator. Good afternoon, and welcome to Kura Oncologyâs first-quarter 2025 conference call. Joining me on the call are Dr. Troy Wilson, President and Chief Executive Officer; Dr. Mollie Leoni, Chief Medical Officer; Brian Powl, Chief Commercial Officer; and Tom Doyle, Senior Vice President of Finance and Accounting.
Before I turn the call over to Dr. Wilson, Iâd like to remind you that todayâs call will include forward-looking statements based on current expectations. Such statements represent managementâs judgment as of today and may involve risks and uncertainties that could cause actual results to differ materially from expected results. Please refer to Kuraâs filings with the SEC, which
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
